Ratings Moves: HVB,...
Health Care: Drugs
Osiris Therapeutics Inc. (OSIR: NASDAQ)
$10.98 0.13 | 1.20%
05/22/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 1.85M | 1.66M | 1.44M | 1.31M |
| Receivables | 3.06M | 728.00K | 1.93M | 1.14M |
| Inventories | 1.28M | 767.00K | 510.00K | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 39.04M | 51.42M | 73.95M | 102.80M |
| Property, Plant & Equipment, Gross | 5.56M | 5.23M | 5.15M | 5.00M |
| Accumulated Depreciation & Depletion | 3.45M | 2.77M | 2.02M | 1.27M |
| Property, Plant & Equipment, Net | 2.11M | 2.46M | 3.13M | 3.73M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 317.00K | 392.00K | 705.00K | 1.06M |
| Total Non-Current Assets | 2.43M | 2.86M | 3.83M | 4.80M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 41.46M | 54.27M | 77.78M | 107.60M |
| Accounts Payable | 5.00M | 4.69M | 5.57M | 9.01M |
| Short Term Debt | 44.00K | 0.00 | 0.00 | 3.00K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 412.00K |
| Total Current Liabilities | 5.04M | 8.02M | 46.53M | 50.44M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 369.00K | 430.00K | 3.80M | 44.60M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 531.00K | 430.00K | 3.80M | 44.60M |
| Total Liabilities | 5.57M | 8.46M | 50.33M | 95.04M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 35.89M | 45.82M | 27.46M | 12.56M |
| Common Par | 33.00K | 33.00K | 33.00K | 33.00K |
| Additional Paid In Capital | 279.27M | 278.09M | 274.65M | 272.96M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -243.39M | -232.33M | -247.22M | -260.34M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -20.00K | 20.00K | -3.00K | -88.00K |
| Total Capitalization | 35.89M | 45.82M | 27.46M | 12.56M |
| Total Equity | 35.89M | 45.82M | 27.46M | 12.56M |
| Total Liabilities & Stock Equity | 41.46M | 54.27M | 77.78M | 107.60M |
| Total Common Shares Outstanding | 32.88M | 32.83M | 32.79M | 32.77M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 32.86M | 32.82M | 32.78M | 32.74M |
| Diluted Weighted Shares Outstanding | 32.86M | 33.12M | 33.10M | 32.74M |
| Number of Employees | 59 | 54 | 56 | 57 |
| Number of Part-Time Employees | 5 | 3 | 3 | 0 |
Portfolios with OSIR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- User2012
- ContributorStocks Rising On Unusual Vo...
- UserPharma
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserE*Trade
- Contributor200 day moving average stocks
Latest OSIR Headlines from TheStreet
- Osiris Therapeutics Inc. Stock Upgraded (OSIR) 03.28.13 | 05:03 am
- 4 Stocks Spiking on Unusual Volume 03.11.13 | 02:03 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Osiris Therapeutics Inc. Stock Downgraded (OSIR) 03.08.13 | 04:03 am
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Under-$10 Stocks Due to Surge 12.27.12 | 01:12 pm
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris 10.05.12 | 06:10 am
- Biotech Stock Mailbag: Mela, Osiris, Talon 08.03.12 | 06:08 am
Press Releases for OSIR
- Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference - Business Wire 03.14.13 | 07:03 am
- Osiris Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.06.13 | 08:03 am
- Osiris Therapeutics Establishes Direct Sales Force For Grafix® - Business Wire 03.01.13 | 07:03 am
- Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.22.13 | 05:02 pm
- Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal® - Business Wire 02.19.13 | 07:02 am
- Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge - Business Wire 02.18.13 | 07:02 pm
- Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 04:11 pm
- Osiris Therapeutics Reports Third Quarter 2012 Financial Results - Business Wire 11.05.12 | 08:11 am
- Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call - Business Wire 10.29.12 | 04:10 pm
- Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer - Business Wire 10.22.12 | 04:10 pm
Partner Headlines for OSIR
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? - Seeking Alpha 02.27.13 | 09:02 am
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- Neutral on Osiris - Analyst Blog - NASDAQ 09.10.12 | 09:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Healthcare Biz Review: Osiris ACCUSED, Chelsea's BAD NEWS - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Osiris' Prochymal Encourages - Analyst Blog - Zacks 07.03.12 | 05:07 pm
- 6 Profitable Small Cap Healthcare Stocks Holding Large Cash Reserves - Seeking Alpha 06.22.12 | 07:06 pm
